Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5105-5111

  Aklillu, Eleni ^a   Øvrebø, Steinar ^c   Botnen, Ingrid V ^c   Otter, Charlotta ^d   Ingelman Sundberg, Magnus ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDRO 7,8 DIHYDROXYBENZO[A]PYRENE; ALANINE; ARGININE; ASPARAGINE; BENZO[A]PYRENE; CYTOCHROME P450 1B1; GLYCINE; LEUCINE; OXIDOREDUCTASE; POLYCYCLIC AROMATIC HYDROCARBON; SERINE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER SUSCEPTIBILITY; CATALYSIS; CIGARETTE SMOKING; CONTROLLED STUDY; ENZYME ANALYSIS; GENE MAPPING; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROLOGOUS EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KINETICS; LUNG CANCER; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; SACCHAROMYCES CEREVISIAE; SINGLE NUCLEOTIDE POLYMORPHISM; YEAST;

EID: 20444486976     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0113     Document Type: Article

References (47)

1. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44.
2. Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter TR. Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1998;19:1847-53.
3. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
4. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
5. Spivack SD, Hurteau GJ, Reilly AA, Aldous KM, Ding X, Kaminsky LS. CYP1B1 expression in human lung. Drug Metab Dispos 2001;29:916-22.
6. Spivack SD, Hurteau GJ, Fasco MJ, Kaminsky LS. Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res 2003;9:6002-11.
7. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 2004;199:210-9.
8. Shimada T, Gillam EM, Oda Y, et al. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem Res Toxicol 1999;12:623-9.
9. Luch A, Schober W, Soballa VJ, et al. Metabolic activation of dibenzo[a]pyrene by human cytochrome -P450 1A1 and P450 1B1 expressed in V79 Chinese hamster cells. Chem Res Toxicol 1999;12:353-64.
10. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279:23847-50.
11. Port JL, Yamaguchi K, Du B, et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis 2004;25:2275-81.
12. Spencer DL, Masten SA, Lanier KM, et al. Quantitative analysis of constitutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes. Cancer Epidemiol Biomarkers Prev 1999;8:139-46.
13. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996;56:2979-84.
14. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-31.
15. Wu MF, Wu WJ, Chang GC, et al. Increased expression of cytochrome P4501B1 in peripheral leukocytes from lung cancer patients. Toxicol Lett 2004;150:211-9.
16. Buters JT, Sakai S, Richter T, et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz [a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A 1999;96:1977-82.
17. Heidel SM, MacWilliams PS, Baird WM, et al. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene. Cancer Res 2000;60:3454-60.
18. Tang YM, Wo YYP, Stewart J, et al. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 1996;271:28324-30.
19. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586-94.
20. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209-16.
21. Sasaki M, Tanaka Y, Okino ST, et al. Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin Cancer Res 2004;10:2015-9.
22. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor a and estrogen receptor β expressions. Cancer Res 2003;63:3913-8.
23. Thier R, Bruning T, Roos PH, Bolt HM. Cytochrome P450 1B1, a new keystone in gene-environment interactions related to human head and neck cancer? Arch Toxicol 2002;76:249-56.
24. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-404.
25. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33.
26. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003;89:1524-9.
27. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity: and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-6.
28. dxTanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 2002;296:820-6.
29. Zheng W, Xie DW, Jin F, et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:147-50.
30. Rylander-Rudqvist T, Wedren S, Granath F, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 2003;24:1533-9.
31. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038-41.
32. Willey JC, Coy EL, Frampton MW, et al. Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Mol Biol 1997;17:114-24.
33. Bartsch H. DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. Mutat Res 1996;340:67-79.
34. Oscarson M, Gullsten H, Rautio A, et al. Genotyping of human cytochrome P450 2A6 (CW2A6), a nicotine C-oxidase. FEES Lett 1998;438:201-5.
35. Urban P, Cullin C, Pompon D. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. Biochimie 1990;72:463-72.
36. McLellan RA, Oscarson M, Hidestrand M, et al. Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys 2000;378:175-81.
37. Mollerup S, Ovrebo S, Haugen A. Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int J Cancer 2001;92:18-25.
38. Zhang P, Sheng H, Morabia A, Gilliam TC. Optimal step length EM algorithm (OSLEM) for the estimation of haplotype frequency and its application in lipoprotein lipase genotyping. BMC Bioinformatics 2003;4:3.
39. Chen H, Howald WN, Juchau MR. Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos 2000;28:315-22.
40. Bejjani BA, Lewis RA, Tomey KF, et al. Mutations in COT1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am J Hum Genet 1998;62:325-33.
41. Libby RT, Smith RS, Savinova OV, et al. Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science 2003;299:1578-81.
42. Michels-Rautenstrauss KG, Mardin CY, Zenker M, Jordan N, Gusek-Schneider GC, Rautenstrauss BW. Primary congenital glaucoma: three case reports on novel mutations and combinations of mutations in the GLC3A (CYP1B1) gene. J Glaucoma 2001;10:354-7.
43. Melki R, Colomb E, Lefort N, Brezin AP, Garchon HJ. CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma. J Med Genet 2004;41:647-51.
44. Shimada T, Watanabe J, Inoue K, Guengerich FP, Gillam EM. Specificity of 17β-oestradiol and benzo[a]-pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica 2001;31:163-76.
45. Mammen JS, Pittman GS, Li Y, et al. Single amino acid mutations, but not common polymorphisms, decrease the activity of CYP1B1 against (-)benzo[a]-pyrene-7R-trans-7,8-dihydrodiol. Carcinogenesis 2003;24:1247-55.
46. Bandiera S, Weidlich S, Harth V, Broede P, Ko J, Friedberg T. Proteasomal degradation of human cytochrome P4501B1 (CYP1B1): effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2004;67:435-43.
47. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, De Vivo I. Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 2004;25:559-65.